TKI – September 2020 TKI – September 2020 BeiGene announced acceptance and priority review by Health Canada for Brukinsa (zanubrutinib) in Waldenstrom’s macroglobulinemia (WM) 09 Sep 2020 Brukinsa (Zanubrutinib; Bruton’s tyrosine kinase (BTK) inhibitor) – BeiGene Data for submission to […]
TKI – September 2020 TKI – September 2020 European Commission approved use of Imbruvica in combination with Mabthera for 2L+ chronic lymphocytic leukemia (CLL) 07 Sep 2020 Imbruvica (Ibrutinib; Bruton’s tyrosine kinase (BTK) inhibitor) – Johnson & Johnson/Abbvie Imbruvica is […]
TKI – September 2020 TKI – September 2020 FDA accepted filing of new drug application for Tepotinib for the treatment of patients with metastatic NSCLC with METex14 skipping alterations 25 Aug 2020 Tepotinib (c-Met kinase inhibitor) – EMD Serono, US […]
TKI – September 2020 TKI – September 2020 Exelixis submitted sNDA to FDA for Cabometyx (cabozantinib) in combination with Opdivo (nivolumab) for advanced renal cell carcinoma 24 Aug 2020 Cabometyx (Cabozantinib; Met kinase inhibitor) – Exelixis Submission is based on […]
